Profile cover photo
Profile photo
Elixirgen Scientific
2 followers
2 followers
About
Posts

Post has attachment
https://buff.ly/2s5qapd
BALTIMORE, May 22, 2018 – Elixirgen Scientific’s new kit, Quick-miniBrain™ uses ES/iPSC differentiation to form miniaturized, 3D human brain tissues for drug discovery and toxicity screening. 3D organoid development is an active area of research in life sciences; its potential to reduce drug development costs by improving predictability of drug efficacy and toxicity screening and its potential use in regenerative medicine, such as in transplantation and personalized medicine, has made it a hot field for academia, private institutions, and government institutions alike.
Currently, unresolved issues in production speed, reproducibility, and economy hinder the growth and advancement of 3D organoid development. The Quick-miniBrain™ kit will be the solution for such issues. The Quick-miniBrain™ kit provides 3D mini-brain organoids in 14 days from ESCs/iPSCs at under $900 for the kit itself. Researchers can use their own ESCs/iPSCs to form 3D mini-brain organoids for research into the disease of their choice. The kit works equally well with all ES/iPSC lines with quality pluripotency. For example, ESCs and iPSCs modified by CRISPR/Cas9 can be used to generate 3D mini-brains.
By combining Elixirgen Scientific’s other products/services, researchers can get disease patient-derived mini-brain models produced with iPSCs from the California Institute for Regenerative Medicine’s (CIRM) hPSC repository and or already-differentiating mini-brains through Elixirgen Scientific’s cell differentiation services.
Photo
Add a comment...

Post has attachment
https://buff.ly/2J2Cs9D
CIRM (California Institute for Regenerative Medicine) has featured Elixirgen Scientific on their blog.
Visit CIRM’s “the Stem Cellar” article to see the content.
https://buff.ly/2J5w5SS
Photo
Add a comment...

Post has attachment
Disease Models from Human Pluripotent Stem Cells Now Commercially Available
https://buff.ly/2GFdy18
BALTIMORE, Mar. 28, 2018 – Elixirgen Scientific has begun selling a variety of cell-based human disease models after signing a new agreement, which allows the company to produce and distribute cells differentiated from the California Institute for Regenerative Medicine (CIRM)’s human pluripotent stem cell (hPSC) repository.

Elixirgen Scientific's proprietary technology (Quick-Tissue™) makes highly efficient differentiation of hPSCs, such as induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), possible in under 10 days, the fastest speed in the world for all cell types. Their catalog includes vascular endothelial cells, GABAergic neurons, dopaminergic neurons, cholinergic neurons, skeletal muscle cells, and hepatocytes, with more cell types in continuous development. The products are currently offered both as a reagent kit for researchers and companies, and as a service - customers can send in their iPSCs or ESCs, and have them returned, differentiated into the tissue type of their choice, in one week.

The CIRM hPSC repository features 1,600 cell lines derived from patients with diseases and conditions that are areas of active research, such as Alzheimer's disease (AD), cardiomyopathy, idiopathic pulmonary fibrosis, autism spectrum disorder, hepatitis C, fatty liver disease, cerebral palsy, diabetic retinopathy, and more. The cell lines have detailed, anonymized demographic clinical data and have matched controls, making them very suitable for research into those diseases.

When applied to CIRM's hPSC bank, Elixirgen Scientific's Quick-Tissue™ differentiation technology will be able to provide relevant tissues for any of the 1,600 cell lines. This means that scientists will be able to receive a variety of in vitro differentiated cells such as neurons, vascular endothelial cells, skeletal muscles, and hepatocytes derived from patients with AD, autism, cerebral palsy, fatty liver disease, and other diseases - all with a one-week turnaround time. These differentiated cells are available in the form of frozen cells, live cells in a cell culture flask, live cells in microplates, and live cells on microscopic slides. Elixirgen Scientific hopes to provide researchers in academia and pharmaceutical companies around the world with much needed cell-based human disease models for drug screening, toxicity testing, and other biomedical applications, thereby accelerating discovery of a cure for many diseases.

Further information as well as an order form are now available at https://buff.ly/2GeEK7D.
Photo
Add a comment...

Post has attachment
https://buff.ly/2nckbfX
BALTIMORE, Jan. 25, 2018 – Elixirgen Scientific has published its new protocol video for Quick-Endothelium™ Vascular – mRNA Complete Kit with Optional Drug Selection. The video is published on YouTube ; available in all countries.
The video demonstrates the detailed, step-by-step actions required to be the most successful with the kit. The video’s clear instructions highlight the protocol’s simplicity and robustness, and most of its steps can be applied to other Quick-Tissue Series™ differentiation kits as well. After learning to use one Quick-Tissue™ Series kit, you will immediately be able to apply that knowledge to our other kits.
This protocol video has been highly requested by Quick-Tissue™ Series users worldwide. Elixirgen Scientific plans to release more protocol videos for other differentiation kits. The possibilities are endless – combine various cell types differentiated with Quick-Tissue™ Series from hPSCs including diseased iPSCs for personalized medicine applications and more!
Photo
Add a comment...

Post has attachment
https://buff.ly/2E4T4ev
BALTIMORE, Jan. 24, 2018 – Elixirgen Scientific’s new kit option for Quick-Neuron™ Cholinergic enables high throughput screening for drug discovery and toxicity screening. The new option is called the Quick-Neuron™ Cholinergic - SeV Complete Kit (for a 96-well microplate format). The Baltimore biotech company today released Quick-Neuron™ Cholinergic - SeV Complete Kit (for a 96-well microplate format) to add to its current Quick-Neuron™ Cholinergic product lineups. This new option will help scientists create cholinergic neurons in only 6 to 11 days from their pluripotent stem cells. The new option to receive differentiating cholinergic neurons on a 96-well microplate format is also available through Elixirgen Scientific’s cell differentiation services.
The kit is a part of the Quick-Tissue™ Series – a revolutionary new way to generate human cells, tissues, and organs. The Quick-Tissue™ Series kits’ potent cocktails of transcription factors transform researchers’ stem cells of choice into high-quality and homogeneous tissues in a scalable, speedy manner. The addition of the 96-well microplate format will provide direct access to an off-the-shelf product for high throughput screening of a collection of compounds for drug discovery and toxicity screening.
Photo
Add a comment...

Post has attachment
GABAergic neuron differentiation is now available from Elixirgen Scientific
https://buff.ly/2zGGbZ9

BALTIMORE, Nov. 27, 2017 – Elixirgen Scientific’s new GABAergic neuron differentiation kit can make global Alzheimer’s disease, Parkinson’s disease, and other brain disease research faster and better. The Baltimore biotech company today released Quick-Neuron™ GABAergic with two options using Sendai Virus (SeV) technology and synthetic mRNA. Quick-Neuron™ GABAergic will help scientists create GABAergic neurons in only 10 days. GABAergic neurons are also available through Elixirgen Scientific’s cell differentiation services.

These kits are a part of the Quick-Tissue™ Series – a revolutionary new way to generate human cells, tissues, and organs. The Quick-Tissue™ Series kits’ potent cocktails of transcription factors transform researchers’ stem cells of choice into high-quality and homogeneous tissues in a scalable, speedy manner. The addition of the GABAergic neuron kits to the existing Cholinergic and Dopaminergic neuron kits will advance global neurodegenerative disease research. All kits will fit into wide variety of applications such as drug toxicity screening, drug discovery, 3D bioprinting, tissue chips, and creating mini-brains.
Photo
Add a comment...

Post has attachment
https://buff.ly/2izTxMs
BALTIMORE, Nov. 20, 2017 – Elixirgen Scientific’s new mixed neuron cell differentiation kit will accelerate mini-brain projects including 3D bioprinting and tissue chip development. The Baltimore biotech company today released Quick-Neuron™ Mixed, a lab kit using Sendai Virus (SeV) technology that will help scientists create mixed neurons in a single assay in only 10 days. Mixed neurons are also available through Elixirgen Scientific’s cell differentiation services. Differentiation into multi-types of neurons can be confirmed with anti-TUBB3 (tubulin-β3, a global marker for neurons) and anti-ChAT (choline acetyltransferase, a cholinergic neuron marker), anti-TH (tyrosine hydroxylase, a dopaminergic neuron marker), anti-PVALB (parvalbumin, a GABAergic neuron marker), anti-vGLUT1 (vesicular Glutamate transporter 1, a glutamatergic neuron marker), and anti-TPH2 (tryptophan hydroxylase 2, a serotonergic neuron marker) antibodies.
These kits are a part of the Quick-Tissue™ Series – a revolutionary new way to generate human cells, tissues, and organs. The Quick-Tissue™ Series kits’ potent cocktails of transcription factors transform researchers’ stem cells of choice into high-quality and homogeneous tissues in a scalable, speedy manner.
Photo
Add a comment...

Post has attachment
BALTIMORE, Nov. 14, 2017 – Elixirgen Scientific’s new vascular endothelial cell differentiation kit will accelerate mini-organ projects including 3D bioprinting and tissue chips. The Baltimore biotech company today released Quick-Endothelial Vascular, a lab kit using synthetic mRNA that will help scientists create vascular endothelial cells in only one week. Vascular endothelial cells are also available through Elixirgen Scientific’s cell differentiation services.
There are currently no options in the market for researchers to differentiate human pluripotent stem cells (hPSCs) into vascular endothelial cells except by attempting to replicate publications. Researchers can now easily grow the same hPSC-derived vascular endothelial cells to co-culture or mix with other hPSC derived tissues such as neurons, hepatocytes, and cardiomyocytes to develop mini-organs like the brain, liver, and heart. Elixirgen Scientific expects strong demand from researchers in 3D bioprinting and tissue chips.
https://buff.ly/2zWjG25
Photo
Add a comment...

Post has attachment
https://buff.ly/2xyBgnq
Elixirgen Scientific will be attending the 2017 Tedco's Entrepreneur Expo & Stem Cell Symposium – which will be held at the Hilton Baltimore on Oct 25th. Elixirgen Scientific team members will be be happy to welcome you to the company’s exhibition booth, where its latest reagents and products will be showcased. Our scientists will also attend poster sessions at the Stem Cell Symposium. Our team is looking forward to interacting with Maryland’s local scientists and professionals.
Photo
Add a comment...

Post has attachment
https://buff.ly/2fU17mY
Elixirgen Scientific released Quick-Tissue™ Mesoderm Booster and Quick-Tissue™ Endoderm Booster. These new products accelerate human pluripotent stem cell (hPSC) differentiation into tissues from the mesoderm and endoderm layers by strongly suppressing the pluripotency maintenance program in the hPSCs. Quick-Tissue™ Booster products can be used for existing differentiation protocols. These products are expected to reach wider customers with established protocols with a variety of differentiation induction methods.
These products are intended to be used at the beginning of hPSC differentiation. The booster should be added immediately after the PSCs are put into differentiation conditions. However, users may want to add the booster at alternative timings before or after the culture conditions of hPSC are switched from the pluripotency maintenance to differentiation to further optimize their protocols.
The Mesoderm Booster is already used in Quick-Muscle™ Skeletal and upcoming Quick-Tissue™ Differentiation Kits of mesoderm-derived tissues such as blood and vascular endothelium.

Learn more about Quick-Tissue™ Mesoderm Booster
https://buff.ly/2fRZXrY
Learn more about Quick-Tissue™ Endoderm Booster
Photo
Add a comment...
Wait while more posts are being loaded